Fecal
Parvimonas micra
Peptostreptococcus stomatis
diagnosis and prognosis
enterotoxigenic Bacteroides fragilis
laterally spreading tumor
noninvasive biomarker
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
01
2021
accepted:
20
04
2021
entrez:
28
5
2021
pubmed:
29
5
2021
medline:
29
5
2021
Statut:
epublish
Résumé
Up to now, non-invasive diagnosis of laterally spreading tumor (LST) and prediction of adenoma recurrence after endoscopic resection of LSTs is inevitable. This study aimed to identify a microbial signature with clinical significance of diagnosing LSTs and predicting adenoma recurrence after LSTs colectomy. We performed 16S rRNA sequencing in 24 mucosal samples, including 5 healthy controls (HC), 8 colorectal adenoma (CRA) patients, and 11 LST patients. The differentiating microbiota in fecal samples was quantified by qPCR in 475 cases with 113 HC, 208 CRA patients, 109 LST patients, and 45 colorectal cancer (CRC) patients. We identified differentially abundant taxa among cases and controls using linear discriminant analysis effect size analysis. ROC curve was used to evaluate diagnostic values of the bacterial candidates. Pairwise comparison of AUCs was performed by using the Delong's test. The Mantel-Haenszel hazard models were performed to determine the effects of microbial compositions on recurrence free survival. The microbial dysbiosis of LST was characterized by relative high abundance of the genus Lactobacillus-Streptococcus and the species enterotoxigenic Bacteroides fragilis (ETBF)-Peptostreptococcus stomatis (P. stomatis)-Parvimonas micra (P. micra). The abundance of ETBF, P. stomatis, and P. micra were steadily increasing in LST and CRC groups. P. stomatis behaved stronger value on diagnosing LST than the other two bacteria (AUC 0.887, 95% CI 0.842-0.931). The combination of P. stomatis, P. micra, and ETBF (AUC 0.922, 95% CI 0.887-0.958) revealed strongest diagnostic power with 88.7% sensitivity and 81.4% specificity. ETBF, P. stomatis, and P. micra were associated with malignant LST (P Fecal microbiome signature (
Identifiants
pubmed: 34046355
doi: 10.3389/fonc.2021.661048
pmc: PMC8144651
doi:
Types de publication
Journal Article
Langues
eng
Pagination
661048Informations de copyright
Copyright © 2021 Shen, Li, Li, Zhang, Li, Cui, Gao, Chen, Chen and Fang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Cancer. 2019 May 15;144(10):2381-2389
pubmed: 30365870
BMC Microbiol. 2015 Feb 10;15:24
pubmed: 25880819
Science. 2017 Dec 15;358(6369):1443-1448
pubmed: 29170280
EBioMedicine. 2017 Nov;25:32-40
pubmed: 29033369
Surg Endosc. 2021 Feb;35(2):736-744
pubmed: 32076862
Genome Med. 2016 Apr 06;8(1):37
pubmed: 27056827
Front Cell Infect Microbiol. 2020 Jan 15;9:476
pubmed: 32010645
Gut. 2020 Jul;69(7):1269-1282
pubmed: 31685519
Gastrointest Endosc. 2020 Nov;92(5):1083-1094.e6
pubmed: 32335123
Nat Microbiol. 2019 Dec;4(12):2319-2330
pubmed: 31501538
Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2457-2468
pubmed: 28821976
Mucosal Immunol. 2017 Mar;10(2):421-433
pubmed: 27301879
Cell Host Microbe. 2018 Feb 14;23(2):203-214.e5
pubmed: 29398651
J Exp Med. 2018 Apr 2;215(4):1205-1225
pubmed: 29472497
Nat Commun. 2015 Mar 11;6:6528
pubmed: 25758642
Gastroenterology. 2017 May;152(6):1419-1433.e5
pubmed: 28126350
Crit Rev Oncog. 1996;7(5-6):293-342
pubmed: 9467664
Cancer Discov. 2015 Oct;5(10):1098-109
pubmed: 26201900
Gastrointest Endosc. 2017 Mar;85(3):647-656.e6
pubmed: 27908600
Ann Clin Biochem. 2018 Jan;55(1):59-68
pubmed: 28081635
Endoscopy. 1993 Sep;25(7):455-61
pubmed: 8261988
Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
Nat Rev Microbiol. 2019 Mar;17(3):156-166
pubmed: 30546113
Oncotarget. 2016 Jul 19;7(29):46158-46172
pubmed: 27323816
NPJ Biofilms Microbiomes. 2017 Nov 29;3:34
pubmed: 29214046
Int J Cancer. 2019 May 15;144(10):2516-2528
pubmed: 30415472
Clin Chem. 2018 Sep;64(9):1327-1337
pubmed: 29914865
Gut. 2017 Aug;66(8):1441-1448
pubmed: 27797940
Microbiome. 2018 Apr 11;6(1):70
pubmed: 29642940
Gastroenterology. 2018 Aug;155(2):383-390.e8
pubmed: 29729257
Cell Death Dis. 2019 Sep 12;10(9):675
pubmed: 31515468
Mod Pathol. 2020 Jun;33(6):986-1006
pubmed: 31907377
Genome Res. 2012 Feb;22(2):299-306
pubmed: 22009989
Gut. 2016 Dec;65(12):1973-1980
pubmed: 26311717
Genes (Basel). 2019 Feb 01;10(2):
pubmed: 30717284
Cancer Cell. 2018 Jun 11;33(6):954-964
pubmed: 29657127
Gut. 2015 Jan;64(1):57-65
pubmed: 24986245
Gastrointest Endosc. 2019 Jul;90(1):127-136
pubmed: 30825536
Nature. 2010 Mar 4;464(7285):59-65
pubmed: 20203603
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Braz Dent J. 2016 May-Jun;27(3):318-24
pubmed: 27224567
Gut. 2017 Jan;66(1):70-78
pubmed: 26408641
Curr Opin Gastroenterol. 2017 Nov;33(6):422-427
pubmed: 28877044
United European Gastroenterol J. 2018 Dec;6(10):1569-1577
pubmed: 30574328
Nat Immunol. 2016 Mar;17(3):230-40
pubmed: 26882261
Front Cell Infect Microbiol. 2020 Jan 17;9:449
pubmed: 32010637
Science. 2018 Feb 2;359(6375):592-597
pubmed: 29420293
Cell. 2017 Jul 27;170(3):548-563.e16
pubmed: 28753429
Gut. 2018 May;67(5):882-891
pubmed: 28341746
Nat Med. 2019 Jun;25(6):968-976
pubmed: 31171880
Gastroenterology. 2018 Aug;155(2):529-541.e5
pubmed: 29689266
World J Gastroenterol. 2017 Mar 14;23(10):1780-1786
pubmed: 28348483
Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1381-90
pubmed: 24599709
JNCI Cancer Spectr. 2019 May 22;3(2):pkz034
pubmed: 31360907
Gut. 2016 May;65(5):806-20
pubmed: 25681402